AI Firm Power Analytics Global to Merge with SPAC DMAA in Up to $1 Billion Deal
DMAA is trading near its 52-week low of $10.02 (5.6% above the low).
Summary
Drugs Made In America Acquisition Corp. (DMAA) has entered into a definitive merger agreement to combine with Power Analytics Global, an AI, advanced analytics, and quantum-resistant security company. The deal targets an enterprise value of up to $1.0 billion for Power Analytics Global, with a $300 million floor valuation. This highly anticipated merger follows the recent shareholder approval on May 1st for an extension to complete a business combination, providing a clear path forward for the SPAC. While the merger fulfills DMAA's purpose, existing DMAA shareholders are expected to own only about 10% of the combined entity, indicating significant dilution. The transaction is subject to customary closing conditions, including Nasdaq listing approval and a minimum cash target of $30 million (flexible to $15 million). Investors will closely monitor the closing process and the combined entity's strategy, especially given DMAA's prior disclosures of a going concern warning and material weaknesses in internal controls.
At the time of this announcement, DMAA was trading at $10.58 on NASDAQ in the Technology sector, with a market capitalization of approximately $356.7M. The 52-week trading range was $10.02 to $10.60. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.